# SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis

Study · id `cardio:ct-nct07944066` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07944066](<https://clinicaltrials.gov/study/NCT07944066>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07944066

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1182 participants.

## Technical summary

Registry record NCT07944066. Randomized; quadruple masking; primary purpose treatment. Start 2026-06-10 (actual); primary completion 2031-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1182 participants (planned count; ClinicalTrials.gov record NCT07944066, source copy `cardio:ctgov-nct07944066-2026-11-18`, retrieved 2026-11-18)
- Started: 2026-06-10 (actual) (ClinicalTrials.gov record NCT07944066, source copy `cardio:ctgov-nct07944066-2026-11-18`, retrieved 2026-11-18)
- Primary completion: 2031-06 (anticipated) (ClinicalTrials.gov record NCT07944066, source copy `cardio:ctgov-nct07944066-2026-11-18`, retrieved 2026-11-18)
- Completion: 2031-06 (anticipated) (ClinicalTrials.gov record NCT07944066, source copy `cardio:ctgov-nct07944066-2026-11-18`, retrieved 2026-11-18)
- Countries: South Korea (ClinicalTrials.gov record NCT07944066, source copy `cardio:ctgov-nct07944066-2026-11-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07944066-2026-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis
- Acronym: SAVE-AS
- Condition: Aortic Valve Stenosis
- Intervention (Drug): Enavogliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER
- Collaborator: Daewoong Pharmaceutical Co. LTD.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)
- Registry lists this organization as a collaborator: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 587ffe2bae07a9413c21948221ac54a70d673aca76be702bebfc96cfbcc9dace
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
